Theriva Biologics (TOVX) Free Cash Flow (2010 - 2026)
Theriva Biologics (TOVX) posted quarterly Free Cash Flow of -$2.5 million for Q1 2026, up 48.36% year-over-year from -$1.7 million in Q1 2025, and up 14.78% quarter-over-quarter from -$2.9 million in Q4 2025.
Theriva Biologics (TOVX) Free Cash Flow (2010 - 2026) Analysis & Trends
Theriva Biologics (TOVX) has reported Free Cash Flow for 17 consecutive years, with -$2.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Free Cash Flow rose 48.36% year-over-year to -$2.5 million; the TTM figure through Mar 2026 stood at -$14.4 million (up 14.42% YoY), while the FY2025 annual figure was -$16.7 million, up 1.38% from the prior year.
- Free Cash Flow rose to -$2.5 million in Q1 2026 per TOVX's latest filing, from -$2.9 million in the prior quarter.
- Across five years, Free Cash Flow topped out at -$2.5 million in Q1 2026 and bottomed at -$6.6 million in Q4 2023.
- Historically, Free Cash Flow has averaged -$4.4 million across 5 years, with a median of -$4.5 million in 2022.
- Annual changes were most pronounced in 2022 — Free Cash Flow slumped 107.19% — and 2026, when it soared 48.36%.
- Theriva Biologics' Free Cash Flow stood at -$5.5 million in 2022, then fell by 20.85% to -$6.6 million in 2023, then increased by 28.89% to -$4.7 million in 2024, then jumped by 38.56% to -$2.9 million in 2025, then gained by 14.78% to -$2.5 million in 2026.
- Business Quant data shows TOVX's Free Cash Flow at -$2.5 million in Q1 2026, -$2.9 million in Q4 2025, and -$4.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Theriva Biologics | 10.64 Mn | 10.64 Mn | - | -3.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.09 Mn |
| Jun 30, 2026 | -3.09 Mn |
| Mar 31, 2026 | -2.46 Mn |
| Mar 31, 2026 | -2.46 Mn |
| Dec 31, 2025 | -2.88 Mn |
| Dec 31, 2025 | -2.88 Mn |
| Sep 30, 2025 | -4.34 Mn |
| Sep 30, 2025 | -4.34 Mn |
| Jun 30, 2025 | -4.71 Mn |
| Jun 30, 2025 | -4.71 Mn |
| Mar 31, 2025 | -4.76 Mn |
| Mar 31, 2025 | -4.76 Mn |
| Dec 31, 2024 | -4.69 Mn |
| Dec 31, 2024 | -4.69 Mn |
| Sep 30, 2024 | -3.91 Mn |
| Sep 30, 2024 | -3.91 Mn |
| Jun 30, 2024 | -3.45 Mn |
| Jun 30, 2024 | -3.45 Mn |
| Mar 31, 2024 | -4.88 Mn |
| Mar 31, 2024 | -4.88 Mn |